[News Brief] CeleCor Completes FDA Application for Heart Attack Drug
CeleCor Therapeutics has completed its New Drug Application (NDA) submission to the US Food and Drug Administration (FDA) for investigational…
Global Pharmaceuticals & Supplements
[News Brief] AnHorn Medicines Secures Regulatory Clearances for AH-008
AnHorn Medicines has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration and Index Case designation…
[News Brief] Sonire Therapeutics Receives NEDO Support for HIFU Platform
Sonire Therapeutics KK has received funding through Japan’s New Energy and Industrial Technology Development Organization (NEDO) Deep-Tech Startups Support Program…
[News Brief] Innovent Biologics and Pfizer Sign Oncology Collaboration
China-based Innovent Biologics and Pfizer have entered a global licensing and collaboration agreement to research and develop twelve early-stage cancer…
[News Brief] Everest Medicines Licenses Kidney Disease Therapy to Travere
China-based Everest Medicines has entered an exclusive licensing and collaboration agreement with US-based Travere Therapeutics for the development and commercialisation…
[News Brief] FDA Approves Tremfya Label Expansion for Psoriatic Arthritis
The US Food and Drug Administration (FDA) has approved a label expansion for Tremfya (guselkumab) to include evidence for inhibition…
[News Brief] Pfizer Receives FDA Approval for Expanded Hympavzi Use
Pfizer has received US Food and Drug Administration (FDA) approval for an expanded indication of Hympavzi (marstacimab-hncq) for adults and…
[News Brief] Everest Medicines Licences Sumecigrel for Asia-Pacific Development
Everest Medicines has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co. for the development, registration and commercialisation…
[News Brief] Simcere Pharma Enters Research Collaboration With Stanford Medicine
Simcere Pharmaceutical Group Limited has entered a research collaboration with Stanford University School of Medicine to develop potential treatments for…
[News Brief] Legend Biotech to Present LB2501 Data at EHA 2026
Legend Biotech Corporation has announced that it will present preliminary Phase 1 clinical data for its investigational LB2501 therapy during…